BHVN Biohaven Ltd
Price (delayed)
$23.68
Market cap
$2.42B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.28
Enterprise value
$2.35B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Highlights
The equity has increased by 34% since the previous quarter
BHVN's quick ratio has dropped by 54% year-on-year but it is up by 27% since the previous quarter
Biohaven's net income has plunged by 107% YoY and by 5% from the previous quarter
The EPS has dropped by 62% year-on-year
Key stats
What are the main financial stats of BHVN
Market
Valuations
Earnings
Shares outstanding
102.05M
Market cap
$2.42B
Enterprise value
$2.35B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$885.11M
Net income
-$846.42M
EBIT
-$845.69M
EBITDA
-$837.83M
Free cash flow
-$586.5M
Per share
Balance sheet
Liquidity
EPS
-$9.28
EPS diluted
-$9.28
Free cash flow per share
-$6.43
Book value per share
$4.19
Revenue per share
$0
TBVPS
$6.53
Total assets
$615.11M
Total liabilities
$191.67M
Debt
$32.78M
Equity
$423.44M
Working capital
$384.25M
Debt to equity
0.08
Current ratio
3.49
Quick ratio
3.15
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-159.2%
Return on equity
-237.7%
Return on invested capital
-336.8%
Return on capital employed
-183.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BHVN stock price
How has the Biohaven stock price performed over time
Intraday
4.78%
1 week
-17.95%
1 month
-36.31%
1 year
-53.38%
YTD
-36.6%
QTD
-1.5%
Financial performance
How have Biohaven's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$885.11M
Net income
-$846.42M
Gross margin
N/A
Net margin
N/A
Biohaven's net income has plunged by 107% YoY and by 5% from the previous quarter
The company's operating income has shrunk by 103% YoY and by 4.3% QoQ
Growth
What is Biohaven's growth rate over time
Valuation
What is Biohaven stock price valuation
P/E
N/A
P/B
5.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 62% year-on-year
The stock's P/B is 54% below its last 4 quarters average of 11.7
The equity has increased by 34% since the previous quarter
Efficiency
How efficient is Biohaven business performance
The ROE has plunged by 130% YoY and by 6% from the previous quarter
Biohaven's return on invested capital has shrunk by 106% YoY but it has increased by 11% QoQ
The ROA has plunged by 97% YoY
Dividends
What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BHVN.
Financial health
How did Biohaven financials performed over time
The total liabilities has soared by 125% YoY
The current ratio has dropped by 56% year-on-year but it is up by 21% since the previous quarter
The company's debt is 92% lower than its equity
The equity has increased by 34% since the previous quarter
BHVN's debt to equity is up by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.